Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Dec 13;87(1):30–39. doi: 10.1002/ana.25642

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 The Authors. Annals of Neurology published by Wiley Periodicals, Inc. on behalf of American Neurological Association.

This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Meta‐analysis of Mendelian randomization estimates for Alzheimer disease (AD) risk according to a lifelong reduction in circulating low‐density lipoprotein cholesterol (LDL‐C) and exposure to the modulation of several related drug targets (n = 24,718 cases, 56,685 controls). The first group of results shows estimates for the effect of a general, long‐term reduction of LDL‐C (achievable by any means) on AD risk. The second to fifth group labels are representative of genetic variation at gene regions (HMGCR, PCSK9, APOB, and NPC1L1) that predict the effects of specific therapeutic target modulation, followed by example drug classes that affect these targets. CI = confidence interval; IGAP = International Genomics of Alzheimer's Project; OR = odds ratio; PGC = Psychiatric Genomics Consortium; SD = standard deviation; SNP = single nucleotide polymorphism.